gretel
09 Aug 2016
Hybridan : new note with 48p target Hybridan's updated note is below, they reckon 48p would bring it in line with sector peers:-[link] 48p share price would be nice "in line with the broader healthcare sector", though even this doesn't appear to include any upside from an Innovenn spin-off.
gretel
04 Aug 2016
New video interview with CEO New 5 minute interview with the CEO about the contract wins FYI:http ://www.proactiveinvestors.co.uk/companies/stocktube/5354/new-contract-build-global-footprint-says-venn-life-sciences-holdings-plc-ceo-5354.html?utm_source=Sign-Up.to&utm_medium=email&utm_campaign=7163-355215-PROACTIVITY+-+Techfinancials+advancing+with+confidence"New contract build global footprint, says Venn Life Sciences Holdings plc CEO13:26 03 Aug 2016 Venn Life Sciences Holdings plc (LON:VENN) says the newly awarded 2.8mln contract allows the group to build a proper international footprintâ€�. The contract is with a European biotech group to carry out a phase II trial. Chief executive Tony Richardson says €™s the kind of business we've really been pursuing.âs a good up-and-coming European bio-tech client operating across many countries,he adds. Venn hails the deal and says vendor qualification is a significant milestone for its Interactive Response Technology and represents an exciting opportunity to grow a global account.The deal allows us to build a proper international footprint, says Richardson. €™s an exciting area to be working in and fits really well with current capabilities. The trial is for an immunotherapeutic treatment for Multiple Sclerosis, involving patients in six countries across Europe and starts in October."
gretel
03 Aug 2016
RNS : more contract wins The good news continues:- a major €2.8m contract win providing further visibility fir this and next year- and successful qualification "as a service provider to a top ten Pharmaceutical client" and the awarding of "an initial project involving thirty sites in China". This is great stuff for a £16m m/cap minnow, and shows the quality and expertise of the management, who've done this all before:[link]
gretel
30 Jun 2016
Terrific AGM statement today - H1 revenues almost double last year's- good visibility for H2 and trading in line for full year- "excellent progress" on Innovenn "independence", with proposals likely in July- new Chairman coming soonGiven the bullishness, it seems to me that VENN may exceed expectations this year, especially with any new contract wins.Great stuff.
gretel
09 Jun 2016
Positive summary from Hybridan Excellent report from Hybridan here. With the core business on a P/E below 10, a large cash pile, good visibility of revenues and Innovenn in the price for free, the upside here could be substantial.[link] growing European Contract Research Organisation (CRO) has reported final results for the year to December 2015. Revenue growth of 135% to €11.47m exceeded our already upgraded revenue forecast of €11.2m. Underlying Group EBITDA showed a €1.9m swing from a €1.53m loss to a profit of €0.39m vs our forecast of €0.49m. We attribute this shortfall to development costs at Innovenn. EBITDA attributable to the CRO business was €0.8m. Depreciation and amortisation charges were €0.46m vs our expectation of €0.22m. The company underwent a step change in scale via the acquisition of Kinesis in Q4 which we understand contributed circa 12% to FY revenues owing to the short period under ownership. With €4.4m revenue booked in Q1 vs €2m in Q1 2015, and the commencement of successful cross selling of services across the enlarged client base, we have confidence in our €17m FY2016 revenue forecast, growth of 48% which we forecast to result in a more than fourfold jump in underlying EBITDA to €1.75m and an adjusted profit of €1.6m equating to adjusted EPS of €0.027c reaching €0.032c by 2018. There is however scope for faster revenue growth and greater margin progression. The company finished the year with cash balances of €3.8m, a strong base from which to negotiate potential acquisition opportunities in Central and Eastern Europe that are being explored as well as selective organic expansion into other areas. Innovenn, Venn’s innovation division, has made good progress with both Labskin and Clarogel through their development phases. These are currently being commercialised.Venn intends to reposition this business such that it has an independent footing, its own source of funding and a value that can be clearly established. The shares are on an adjusted PE multiple of 12.4x for 2016. Innovenn made an EBITDA loss this year of €0.44m. If we simply add back a similar figure to our forecast for next year this puts the company on a sub 10x PE rating, as if it were the CRO business on its own. Even at a share price of 43p (74% above the current share price) this rating is only at 16x these pro-forma earnings broadly in line at the sector, and does not take into account any separate value for Innovenn which has two differentiated market ready integumentary products targeting growing markets."
gretel
07 Jun 2016
Davy initiate coverage today Good news - Davy initiate today with Outperform:[link] and tested: Initiating with an 'Outperform' ratingJune 7 2016DAVY VIEWVenn Life Sciences is a small-cap clinical research organisation (CRO) building scale in an attractive segment of healthcare outsourcing. Now that it is profitable and cash-generative, the business has the potential to grow rapidly, internally and externally. Venn’s valuation – it is on a forward-year P/E of 14.3x and EV/EBITDA of 8.1x – leaves plenty of scope for it to outperform."Hybridan forecast 2.12p EPS this year, so presumably Davy's "forward-year" P/E is actually current year, just different terminology."
gretel
20 May 2016
VENN featured today by Amati Global Amati Global have just emailed out their quarterly newsletter, and VENN get great exposure as one of three featured stocks as follows:[link] Life Sciences is a clinical research organisation providing drug development, clinical trial management and resourcing to pharmaceutical, biotechnology and medical device clients. Venn has adopted a ‘buy and build’ strategy to consolidate a fragmented Europeanmarket and now has operations in Ireland, Germany and France. In targeting acquisitions, Venn looks to fill in the gaps in its portfolio of service offerings as well as adding to its geographic coverage. This has obvious attractions to its clients, who tend to operate globally and prefer to deal with one service provider rather than multiple supplier in multiple territories. Venn has been around for 25 years and has built a good reputation within its market, having completed over 300 clinical trials. It is this experience and high standard of customer service that the business relies upon. Now over 70% of contracts come each year from repeat customers. From an investor’s point of view, this provides good revenue visibility - the order backlog (contracted work) and the pipeline tend to be healthy at the beginning of each financial year, de-risking the market forecasts.Recent contract awards include a €3m contract with a European biotech for an orphan disease; a €2.4m trial for a new stent for a European medical device customer; and a phase IV allergic disease drug trials contract from a global pharmaceutical company. Venn is now held in both Amati VCT plc and Amati VCT 2 plc."
gretel
10 May 2016
Excellent results today Very positive results and outlook.EBITDA of €285k (before amortisation and exceptionals and after depreciation) is well ahead of the £130k forecast.Q1 of this year looks incredibly strong with €4.4m of revenues booked.Innovenn looks intriguing now that it's reached commercialisation, with lots of talk about "maximising shareholder value".Plenty of cash too, so the likelihood of more acquisitions is good.Pleasing stuff.
gretel
29 Apr 2016
Positive new article about VENN New article on VENN on Proactive FYI setting out the investment case quite persuasively.The P/E of 9.1 is interesting given forecasts of 1.85p EPS for this year from Hybridan - perhaps it refers to next year's numbers, or perhaps it's after stripping out the cash pile:[link] the analysts thinkLast month shares were down 20% to 18.5p. But based on current year forecasts, analysts saw this price as offering deep value for a solid cash generative business with good revenue.The shares are on a 9.1x price earnings multiple, a discount of around 50% to the sector, which offers a free cash flow yield of 7.2%, said analysts at Hybridan.The broker estimates revenues of £16.03mln for 2016.The latest trading update suggested the group’s earnings will be at least in line with analyst forecasts. The company now expects revenues for full year 2015 to be more than double the previous year (2014: €4.9m) and to exceed market expectations by at least 15%.Venn said it is now generating free cashflows and will report a positive EBITDA position having recorded a group EBITDA loss, before exceptionals of €1.53m for the previous year."
gretel
24 Mar 2016
Results ahead of expectations! Yippee 
))[link] Company now expects revenues for full year to 31 December 2015 to be significantly more than double the previous year (2014: €4.9m) and to exceed market expectations by at least 15%"Plus a €3.4m cash pile.Plus a very bullish outlook.
gretel
12 Jan 2016
Big contract win today Great stuff - a €3.4m contract win is huge for a company this size..The contract sizes are getting much bigger, and it's a vote of confidence from the existing customer too.
gerihatric
11 Jan 2016
Re: Techinvest He did.....it is in his12 for 2016 and I have no doubt this has been a contributing factor in the SP rise today.....wish I had bought more on Friday!
gretel
11 Jan 2016
Beaufort say Buy today Beaufort Securities have summarised as follows this morning:"Venn Life Sciences (VENN.L, 23.0p) - Speculative BuyOn Friday, Venn Life Sciences (Venn) released a trading update for the year ended 31st December 2015. The company expects revenue for the full year to be at least twice as much compared to last year (2014: €4.9m). Cash at the end of period stood at €3.4m. In a separate announcement, Venn informed that David Evans, Non-Executive Chairman, resigned from the board, in line with his personal commitment to reduce his number of non-executive chairman roles currently undertaken.Our view: In 2015, Venn experienced a sharp jump in revenue, led by some major contracts won during the period. Moreover, the addition of drug development and service capabilities has enhanced the company’s service offerings. Furthermore, Venn is seeking acquisition opportunities in Central and Eastern Europe in wake of huge opportunities in the region at minimal costs. Venn is well funded with sufficient cash to expand its international coverage. Overall, the company is well placed, with a strong balance sheet and enhanced contract base, to maintain its growth momentum in 2016. Therefore, we maintain our Speculative Buy rating on the stock. "
gerihatric
08 Jan 2016
Techinvest has been keen on Venn. He made it in his list of best buys for the 2nd half of 2015 at 21p and last January at 17p and in November said had a growing client base and a strong pipeline-it will be interesting to see if he puts it in his "naps" for 2016 tomorrow-I think the chances are good he will recommend it again as he has already done in 2015.
gretel
08 Jan 2016
Terrific trading statement today Excellent trading statement, with doubled sales of likely €10m+ and plenty of cash (€3.4m) going forward.Looking very strong now.
